Status:
RECRUITING
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Lead Sponsor:
Krystal Biotech, Inc.
Conditions:
Epidermolysis Bullosa Dystrophica
Epidermolysis Bullosa Dystrophica, Recessive
Eligibility:
All Genders
6+ years
Brief Summary
This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
Detailed Description
The objective of this study is to characterize the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB). Patients will be followed via remote weekly symptom dia...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The subject or their respective legal guardian must have read, understood, and signed an Institutional Review Board (IRB) approved Informed Consent/Assent Form and must be able to and willing to follow study procedures and instructions.
- Age 6 months or older at time of Informed Consent/Assent.
- Prior genetic diagnosis of DEB due to mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Exclusion
Key Trial Info
Start Date :
August 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06563414
Start Date
August 2 2024
End Date
December 1 2025
Last Update
July 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Krystal Biotech
Pittsburgh, Pennsylvania, United States, 15203